Osteoarthritis therapy--are there still unmet needs?

Area of Science:

• Pharmacology
• Rheumatology
• Gastroenterology

Background:

• Non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors are standard osteoarthritis treatments.
• These drugs carry risks of gastrointestinal, renal, and cardiovascular adverse effects, highlighting an unmet need for safer options.

Purpose of the Study:

• To review the safety profiles of NSAIDs and selective COX-2 inhibitors in osteoarthritis management.
• To explore novel therapeutic agents for osteoarthritis with improved tolerability.

Main Methods:

• Literature review of adverse effects associated with NSAIDs and selective COX-2 inhibitors.
• Identification and preliminary assessment of novel osteoarthritis therapies.

Main Results:

• Both NSAIDs and selective COX-2 inhibitors share risks for gastrointestinal complications, including delayed ulcer healing and potential bleeding.
• Selective COX-2 inhibitors exhibit similar negative impacts on kidney function as NSAIDs, causing electrolyte disturbances, edema, and hypertension.
• Cardiovascular risks associated with selective COX-2 inhibitors require further investigation.

Conclusions:

• There is a significant need for safer osteoarthritis treatments due to the adverse effects of current NSAIDs and COX-2 inhibitors.
• Novel agents like COX-inhibiting nitric oxide donors and licofelone (a lipoxygenase/COX inhibitor) demonstrate potential for improved tolerability.
• These new therapies may offer advantages over existing NSAIDs and selective COX-2 inhibitors for osteoarthritis management.